Wednesday, May 24, 2017 4:21:51 PM
The drug, emricasan, was tested in combination with another drug also in testing, birinapant. The study, performed in mice and human cancer cell cultures, demonstrated that the combo was more effective at killing the leukemic cells than birinapant alone.
A paper on the study was published Wednesday in the journal Science Translational Medicine. Paul G. Ekert and John Silke were the paper's senior authors and the first author was Gabriela Brumatti. All are of the University of Melbourne in Victoria, Australia. It can be found at http://j.mp/emribiri.
http://www.sandiegouniontribune.com/business/biotech/sdut-emricasan-liver-cancer-2016may19-story.html
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM